GLP-1 & Incretin Science

Semaglutide and Liver Disease: What ESSENCE Tested

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

ESSENCE is a Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis, registered as NCT04822181 with 1,205 participants. Sanyal and colleagues published results in the New England Journal of Medicine in June 2025.

Key facts

Trial
ESSENCE, NCT04822181
Phase
3
Enrolment
1,205
Status
Active, not recruiting
Condition
MASH (formerly NASH)
Published
NEJM 2025 (PMID 40305708)
Design paper
Newsome 2024 (PMID 39412509)

What MASH is

Metabolic dysfunction-associated steatohepatitis: fat accumulation in the liver accompanied by inflammation and liver cell injury, which can progress to fibrosis and cirrhosis. It was called NASH (non-alcoholic steatohepatitis) until a renaming that shifted the emphasis from what the condition is not to what drives it. The trial registration still carries the older name.

Why an incretin was an obvious candidate

MASH sits downstream of the same metabolic disturbance that produces obesity and type 2 diabetes. A drug that substantially reduces body weight and improves glycaemic control is acting on the upstream drivers, so the hypothesis is mechanistically coherent rather than opportunistic. Whether the benefit is weight reduction alone or something more direct is a separate and unsettled question.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why liver trials are unusually difficult

The endpoints require liver biopsy. Histological scoring of inflammation, ballooning and fibrosis is a pathologist's judgement, not a machine reading, and inter-observer variability is well documented. Trials therefore need central reading, and even then the endpoint is noisier than a blood pressure or an HbA1c. This is a substantial reason MASH drug development has been slow.

What the trial reports on

Resolution of steatohepatitis without worsening of fibrosis, and improvement in fibrosis without worsening of steatohepatitis. These are the two histological endpoints this field has converged on. Both are surrogates for what actually matters, which is progression to cirrhosis, liver failure and death over timescales no trial can practically cover.

The regulatory consequence of that

Because the endpoints are surrogates, approvals in this area have come through accelerated pathways that require confirmatory evidence afterwards. That is a different kind of approval from one granted on clinical outcomes, and the distinction is rarely made in coverage.

What it does not concern

Research material. Semaglutide is a licensed medicine, ESSENCE is a registered trial conducted under clinical supervision, and nothing supplied here is semaglutide, related to it, or an alternative to any liver treatment.

Frequently asked questions

Why are liver trials so difficult?

The endpoints require biopsy and histological scoring, which is a pathologist's judgement with documented inter-observer variability.

Are the endpoints clinical outcomes?

No. They are histological surrogates for progression to cirrhosis and death, which no trial can practically follow to completion.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.